Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

被引：4
|
作者：
Rodrigues, M. J. [1 ,2 ]
Albiges-Sauvin, L. [2 ,3 ]
Wassermann, J. [2 ,4 ]
Cottu, P. H. [1 ]
机构：
[1] Inst Curie, Dept Med Oncol, Paris, France
[2] AERIO, Paris, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Hop Rene Huguenin, Inst Curie, Dept Med Oncol, St Cloud, France
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 11期
关键词：
CANCER;
D O I：
10.1093/annonc/mdr308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2530 / 2530
页数：1
相关论文
共 50 条
  • [11] New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors
    Sonnenblick, Amir
    Fumagalli, Debora
    Azim, Hatem A., Jr.
    Sotiriou, Christos
    Piccart, Martine
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6242 - 6246
  • [12] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Petrelli, Fausto
    Barni, Sandro
    MEDICAL ONCOLOGY, 2011, 28 (02) : 401 - 408
  • [13] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Fausto Petrelli
    Sandro Barni
    Medical Oncology, 2011, 28 : 401 - 408
  • [14] For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
    Zhou, Qiong
    Yin, Wenjin
    Du, Yueyao
    Lu, Jinsong
    PLOS ONE, 2014, 9 (01):
  • [15] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [16] Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study
    Sasada, S.
    Takahashi, Y.
    Terata, K.
    Kida, K.
    Sagara, Y.
    Ueno, T.
    Anan, K.
    Suto, A.
    Kanbayashi, C. K.
    Takahashi, M.
    Nakamura, R.
    Ishiba, T.
    Tsuneizumi, M.
    Nishimura, S.
    Naito, Y.
    Hara, F.
    Iwata, H.
    Shien, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S342 - S342
  • [17] Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma
    Hanrahan, Emer O.
    Gonzalez-Angulo, Ana M.
    Giordano, Sharon H.
    Rouzier, Roman
    Broglio, Kristine R.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 4952 - 4960
  • [18] Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
    Skedgel, C.
    Rayson, D.
    Younis, T.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1834 - 1840
  • [19] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [20] Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
    Wu, Junzhao
    Lv, Minhao
    Yuan, Peng
    Ma, Youzhao
    Tian, Peiqi
    Li, Lianfang
    Wang, Chengzheng
    Lu, Zhenduo
    Yan, Min
    Chen, Xiuchun
    Liu, Zhenzhen
    GLAND SURGERY, 2022, 11 (08) : 1341 - +
12345